Related references
Note: Only part of the references are listed.MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period
T. Kanni et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
Dinesh Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients
Gianluca Nazzaro et al.
DERMATOLOGIC THERAPY (2021)
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications
Alain Lescoat et al.
CURRENT OPINION IN RHEUMATOLOGY (2021)
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 A Randomized Clinical Trial
Roberto Caricchio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Evdoxia Kyriazopoulou et al.
NATURE MEDICINE (2021)
Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice
Errol P. Prens et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin
Laura C. Burzynski et al.
IMMUNITY (2019)
Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?
Konstantinos Ntelis et al.
CURRENT RHEUMATOLOGY REPORTS (2019)
MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study
Theodora Kanni et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study
Tamas Hickish et al.
LANCET ONCOLOGY (2017)
Interstitial lung disease in systemic sclerosis: current and future treatment
Roberto Giacomelli et al.
RHEUMATOLOGY INTERNATIONAL (2017)
The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis
Konstantinos Ntelis et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review
Y. Mostmans et al.
AUTOIMMUNITY REVIEWS (2017)
Interleukin 1α and the inflammatory process
Nelson C. Di Paolo et al.
NATURE IMMUNOLOGY (2016)
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
Dinesh Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Advances in pathogenesis and treatment of systemic sclerosis
C. P. Denton
CLINICAL MEDICINE (2015)
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation
Remi-Martin Laberge et al.
NATURE CELL BIOLOGY (2015)
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
David S. Hong et al.
LANCET ONCOLOGY (2014)
Serum levels of interleukin-1 in patients with systemic sclerosis
Takeo Maekawa et al.
JOURNAL OF DERMATOLOGY (2013)
Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis
N. P. Barlo et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2011)
Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis
Murray Baron et al.
JOURNAL OF RHEUMATOLOGY (2011)
Epithelial Cells Promote Fibroblast Activation via IL-1α in Systemic Sclerosis
Nima Aden et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Inflammatory networks during cellular senescence: causes and consequences
Adam Freund et al.
TRENDS IN MOLECULAR MEDICINE (2010)
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis
C. P. Denton et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Intracellular IL-1α-binding proteins contribute to biological functions of endogenous IL-1α in systemic sclerosis fibroblasts
Yasushi Kawaguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Systemic sclerosis: hypothesis-driven treatment strategies
Christina Charles et al.
LANCET (2006)
Share Paper
